Orive Gorka, Gascón Alicia R, Hernández Rosa M, Pedraz José Luis
Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria-Gasteiz, 01002, Spain.
Trends Biotechnol. 2004 Dec;22(12):612-3. doi: 10.1016/j.tibtech.2004.10.009.
Type 1 diabetes affects an estimated 150 million people worldwide and results from an autoimmune-mediated destruction of insulin-producing beta-cells. In the United States alone more than 16 million people are affected by this disease and it is estimated that spending for diabetes management accounts for one out of every eight healthcare dollars. In this context, scientists are proposing novel therapeutic strategies that might allow a perfect glycemic control of most patients with diabetes.
全球约有1.5亿人患有1型糖尿病,其病因是自身免疫介导的胰岛素生成β细胞破坏。仅在美国,就有超过1600万人受此病影响,据估计,糖尿病管理费用占每八美元医疗保健费用中的一美元。在这种背景下,科学家们正在提出新的治疗策略,有望使大多数糖尿病患者实现完美的血糖控制。